Sorafenib for patients with differentiated thyroid cancer

Lancet. 2015 Jan 17;385(9964):227. doi: 10.1016/S0140-6736(15)60053-8.

Authors

Olivier Huillard¹, Benoit Blanchet², Jean-Philippe Durand³, François Goldwasser³

Affiliations

¹ Departments of Medical Oncology, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France. Electronic address: [email protected].
² Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France.
³ Departments of Medical Oncology, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France.

PMID: 25706705
DOI: 10.1016/S0140-6736(15)60053-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Female
Humans
Male
Niacinamide / analogs & derivatives*
Phenylurea Compounds / therapeutic use*
Thyroid Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Phenylurea Compounds
Niacinamide